Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Dense vs Standard Chemotherapy in Breast Cancer (CALGB 9741)
NCT00003088Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 1997
- Primary completion
- Apr 2003
- Modality
- Targeted Liposomes, Cytokines & Interferons, Stealth (PEGylated) Liposomes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of pegylated liposomal doxorubicin, Paclitaxel Micelles for Injection and cyclophosphamide in breast cancer (4 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Disease Free Survival at 4 years. Started Sep 1997; status: completed.
02
Drugs
pegylated liposomal doxorubicinPaclitaxel Micelles for Injectioncyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00003088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003088.